Control of Colic in Infants by Dietary Supplementation With the Probiotic Lactobacillus Reuteri
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Misty R Ross, MA
- Phone Number: 21 479-254-6772
- Email: mross@chirpresearch.com
Study Locations
-
-
Arkansas
-
Bentonville, Arkansas, United States, 72712
- Recruiting
- Children's Investigational Research Program
-
Contact:
- Misty R Ross, MA
- Phone Number: 21 479-254-6772
- Email: mross@chirpresearch.com
-
Contact:
- Tonya D Hogue, Coordinator
- Phone Number: 22 479-254-6772
- Email: thogue@chirpresearch.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Ifants aged between 14 and 60 days
- Breast fed, exclusively during length of trial
- Diagnosis of infantile colic according to Wessel's criteria i.e paroxysmal fussing in infancy for more than three hours per day, at least three days per week.
- Debut of colic symptoms 6+/-1 days before randomization
- Gestational age between 37 and 42 weeks
- Apgar score higher than 7 at 5 minutes
- Mothers willing to follow a cows mild-free diet (free from mild, yoghurt, cheese etc) during the study period
- Written informed consent from one or both parents
- Stated availability throughout the study period
Exclusion Criteria:
- Major chronic disease
- Gastrointestinal disease but controlled GERD with or without medication is not an exclusion criteria
- Administration of anitbiotics the week before randomization
- Administration of probiotics the week before randomization
- Participation in other clinical trials
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Quadruple
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
* Reduction of daily average crying time to less than 3 hours from baseline to the end of the study period as measured using a daily reporting of crying time by the parents.
Time Frame: 7, 14 and 21 days
|
7, 14 and 21 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of responders versus non-responders with L. reuteri versus placebo at end of the study.
Time Frame: 21 days
|
21 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Bryan M Harvey, M.D., Children's Investigational Research Program
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Colic001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.